Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

NCT07673900 · Recruiting

Last updated 2026-07-12

This clinical trial is testing whether a skin patch (microarray patch) delivering semaglutide is safe and well-tolerated compared to the standard injection in healthy adults who are overweight or obese.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 62 people Planned (estimated).

Who can join Ages 18–60 · all sexes

Timeline Started 2026-06 · est. completion 2027-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07673900 ↗

Description as written by the study sponsor.

VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.

Treatments tested

VX-201 also known as Sema MAP Combination Product

VX-201 is a needle free, shelf-stable, microneedle array patch (MAP) for delivery of semaglutide epi/intra-dermally
semaglutide SC also known as semaglutide, Wegovy Drug

Semaglutide is a long acting GLP-1 analogue with low renal clearance and an elimination half-life of approximately 7 days following subcutaneous administration.

Main thing measured	Type, incidence, and severity of treatment emergent adverse events (TEAEs), including assessment of application site skin sensitivity, vital signs, electrocardiograms (ECGs), and clinical laboratory results)
Sponsor	Terrestrial Bio, Inc.
Conditions studied	Overweight and/or Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07673900 ↗